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Background: In-stent restenosis (ISR) is an important factor endangering the long-term safety and efficacy of
carotid artery angioplasty and stenting (CAS). It is plausible that soft vulnerable plaques are more likely to be injured
during CAS procedure and are therefore more likely to initiate the cascade finally leading to ISR. The aim of this
study was to investigate if plaque morphology detected by a simple applicable Duplex ultrasound score before
CAS can be used as a predictor for ISR.
Methods: Within a prospectively collected single-centre CAS database of 281 patients (comprising 300 arteries) with
high-grade carotid artery stenosis, who underwent CAS between May 2003 and January 2013, we conducted a nested
case–control study. Plaque morphology before CAS was analysed by a blinded investigator and each parameter of the
Total Plaque Risk Score (TPRS) as well as the whole score was evaluated with regard to its diagnostic validity for ISR.
Results: We analysed the data of 10 patients with ISR and 50 patients without ISR. There were no significant differences
with respect to baseline characteristics, vascular risk factors, and degree of stenosis between patients with and without
ISR. The duration of follow-up was longer in patients with ISR (p = 0.024) and these patients were more likely to show
increased PSV (p = 0.012) immediately after CAS than patients without ISR. Neither individual parameters of the TPRS
score nor the score as a whole were suitable as a diagnostic test for ISR development.
Conclusions: In the present study we could demonstrate that the non-contrast enhanced DUS of the pre-interventional
plaque formation cannot be used as a predictor for the development of ISR. Evaluating a more sophisticated, but not
routinely available approach e.g. by ultrasound based plaque perfusion imaging or CT based plaque analysis could be
helpful in the future in order to assess the role of plaque morphology in the context of ISR development.
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Atherosclerotic stenosis of the internal carotid artery (ICA)
is known as a major risk factor for disabling stroke and
death. Carotid endarterectomy (CEA) in combination with
best medical treatment of concomitant cerebrovascular risk
factors is currently the therapy standard for patients with
symptomatic ICA stenosis and some patients with high-* Correspondence: jliman@gwdg.de
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reproduction in any medium, provided the orgrade asymptomatic ICA stenosis. Nevertheless, carotid
angioplasty and stenting (CAS) has been used as the treat-
ment of first choice in many centres, despite the fact that
randomized controlled trials and subsequent meta-analyses
could not provide evidence for a general superiority of
CAS over CEA [1-6]. However, the results of these trials
have been interpreted very controversially resulting in con-
flicting recommendations in various current guidelines
[7,8]. Although CEA is still the goldstandard therapy for
most patients, there is accumulating evidence that a sub-
group of patients aged <70 years may benefit from a CASLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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long-term safety and efficacy of CAS is an in-stent resten-
osis (ISR); indeed, we could recently show that the com-
bined stroke and death rate during long-term follow-up
was significantly higher in the group of patients suffering
from ISR compared with patients without ISR [12]. There-
fore, it is of highest interest to identify predictors of ca-
rotid artery in-stent restenosis in CAS-treated patients.
A possible predictor of ISR could be the lesion charac-
teristics of the stenotic artery. Up to now it could
be shown that (regardless of a CAS intervention) a com-
pound score of plaque surface irregularity, echoluency and
texture characteristics can predict the risk of stroke [13].
Furthermore, new ischemic lesions as detected with MRI
after CAS are closely related to the plaque vulnerability. It
could also be shown that fibrolipid plaques are associated
with a higher burden of new ischemic lesions [14,15].
Taking pathophysiological mechanisms of ISR develop-
ment into account, it seems plausible that plaque morph-
ology is not only a predictor of ischemic events during
CAS, but may also be associated with a higher risk of the
development of an ISR. We know from coronary artery
angioplasty and stenting that vascular injury, which is
caused by balloon inflation and stent placement, leads to
inflammatory processes, which, themselves, play the piv-
otal role in the pathogenesis of ISR, finally causing neoin-
timal proliferation through the stent meshes [16-18]. In
the context of CAS Petric et al. demonstrated that calci-
fied plaques bear a lower risk of arterial injury although
they could be exposed to higher dilation pressure while
CAS. The authors concluded that this might reduce the
initial stimulus for ISR [19].
The Total Plaque Risk Score (TPRS) described by Prati
et al. [13] has proven its value in the prediction of future
strokes in asymptomatic patients and considers 1) the
degree of the stenosis, 2) echogenicity, 3) texture, and
4) surface characteristics. We used this score, which can
easily be evaluated with the commonly available, cost-
effective and non-invasive Duplex ultrasound investiga-
tion, in order to investigate the influence of plaque
morphology on ISR development.
Methods
Patients
The design of the core study has been published in de-
tail, recently [12]. Within a prospectively created single-
centre CAS database of 281 patients (comprising 300
arteries) we conducted a nested case–control study. All
patients suffered from a symptomatic carotid artery
stenosis ≥70% or an asymptomatic carotid artery sten-
osis ≥90% (degree of stenosis was measured according to
the European guidelines (ECST) [20]) and underwent
CAS between May 2003 and January 2013. For inclusion
in this study, only patients with a complete and well-documented pre-interventional Duplex ultrasound were
considered. A total of 14 patients (4.7%) developed ISR
during long-term follow-up within our database. Of
these 14 patients, 10 (71.4%) had well analysable, pre-
interventional Duplex ultrasound image. Furthermore, a
control-group of 50 patients (23.8%) without ISR during
long-term follow-up was randomly chosen from those
meeting above named inclusion criteria for cases (n =
210). All cardiovascular risk factors and clinical outcome
parameters were recorded by experienced stroke neurol-
ogists (K.G. and K.W.).
The current study has been conducted in accordance
with International Conference on Harmonisation/Good
Clinical Practice (ICH/GCP) guidelines and was ap-
proved by the local Ethics committee of the University
Hospital Göttingen, Germany.
Doppler and duplex sonography
The diagnosis of carotid artery stenosis and ISR was made
by carotid duplex ultrasound imaging using a combination
of direct and indirect criteria, which have been described
in detail, recently [12,21]. Peak systolic flow velocities
(PSV) within the stenosis and post-stenotic internal ca-
rotid artery, end diastolic flow velocity in the stenosis, in-
ternal carotid artery/common carotid artery PSV ratio,
and pre-stenotic and post-stenotic frequency patterns
were determined as direct criteria for the local degree of
stenosis. Flow characteristics of the supra-trochlear artery
and the anterior cerebral artery as well as the pulsatility of
the ipsilateral common carotid artery were taken into ac-
count as indirect criteria for a high-grade stenosis. The de-
gree of carotid stenosis at baseline was graded according
to angle corrected maximum intrastenotic peak systolic
velocities according to ECST criteria as follows: baseline
stenosis ≥70% = PSV ≥200 cm/s, baseline stenosis ≥80% =
PSV ≥300 cm/s, baseline stenosis ≥90% = PSV ≥400 cm/s.
As there is a lack of valid ultrasound criteria for the
definition of an ISR and as the current literature sup-
poses different criteria, [5,6,22] we used locally adopted
criteria with a PSV ≥300 cm/s as a key feature represent-
ing an ISR of ≥70%, as this velocity is best evaluated
in the literature and consistent with our CT or angiog-
raphy based control examinations of ISR detected by
DUS [12,21].
Regarding to plaque morphology we collected data with
respect to four different plaque qualities as described in
detail by Prati et al. [13] (Table 1). The first parameter is
the degree of stenosis. According to Prati et al., patients
with a stenosis >40% using NASCET criteria were scored
with “1”. All of our patients fulfilled that criterion. Secondly,
the echogenicity was graded from 1 to 3 according to the
Gray-Weale modified score [23-25]. Thirdly, the texture
was graded “1” if a heterogeneous echo pattern was de-
tected and “0” if a homogeneous echo pattern was present.
Table 1 The Total Plaque Risk Score (TPRS)
Parameter Score = 0 Score = 1 Score = 2 Score = 3
I) Degree of stenosis < 40% (NASCET) ≥ 40% (NASCET)
II) Echogenicity Low echogenicity or echolucency Intermediate echogenicity Hyper-echogenicity
III) Texture Homogeneous Heterogeneous
IV) Surface Smooth Irregular
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plaque contour was smooth or “1” if it was irregular. The
TPRS was computed by adding the values of the four pa-
rameters and could range from 0 to 6 as summarized in
Table 1. We also composed an alternative score based on
the latter three parameters with inversed values for the par-
ameter “echogenicity”, because an anechoic plaque is as
well as a heterogeneous texture and an irregular surface
considered being associated with a higher vulnerability of
the plaque (Figure 1).
All examinations were performed according to a stan-
dardized protocol in the same vascular laboratory with
the same ultrasound equipment (Acuson Sequoia™ 512,
Siemens, San José, CA) under the supervision of an ex-
perienced, board certified vascular neurologist (K.G.).
Patient data sets were collected by a second person of
the study group (K.W.) and subsequently analysed by an
experienced, board certified vascular neurologist, blinded
to outcome parameters (J.L.).
CAS procedure
CAS was carried out by experienced interventional neu-
roradiologists under anaesthesiological stand-by using a
transfemoral approach. Stent-type and the use of filter-
based neuroprotection devices were chosen at the dis-
cretion of the interventionalists. Only patients scheduled
for elective CAS were recorded, patients in unstableFigure 1 Shown are two plaque types with different plaque scores. Th
echogenicity; heterogenous texture and irregular surface. Plaque score: 4; r
<40%, low echogenicity, homogeneous texture and smooth surface. Plaquclinical conditions or with stroke in evolution were ex-
cluded. All patients received orally administered acetyl-
salicylic acid (100 mg/d) and clopidogrel (75 mg/d) at
least 3 days before the procedure or if that was not
possible due to CAS procedure earlier than 3 days after
admission they received a loading dose of 600 mg clopi-
dogrel and 300 mg of acetylsalicylic acid. Clopidogrel
was continued for 6 to 12 weeks after CAS in a daily
dosage of 75 mg and aspirin was administered life-long
in a dosage of 100 mg/d. After being routinely moni-
tored in our intensive care or stroke unit overnight for
at least one day all patients could be discharged to nor-
mal ward or home.
Follow-up protocol
All patients were seen for serial duplex sonography and
clinical follow-up at the hospital’s outpatient clinic at 3,
6, and 12 months after the CAS-procedure and every
6 months thereafter.
Statistical analysis
Categorical variables were expressed as count and per-
centages, continuous values as mean ± standard deviation
(SD), or as median values with the corresponding inter-
quartile range (IQR) as appropriate. For univariate com-
parisons of categorical data, Chi-square tests with Yates’
correction and Fisher’s exact test were used as appropriate.e left plaque would be classified as stenosis < 40%; intermediate
eversed score: 4. The right plaque would be classified as stenosis
e score: 1, reversed score: 4.
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ables, two-sided t-tests and Wilcoxon-Ranksum tests were
applied dependent on distribution features and variances
of the outcome variable.
TPRS was evaluated as a diagnostic test by using
receiver-operating characteristic (ROC) curves. Sensitiv-
ity and specificity was calculated for different cut-off
values to establish the best cut-off according to the
Youden-index. Predictive values were calculated with the
Bayes formula using prevalence estimates from the ini-
tial cohort study.
In an exploratory secondary analysis, respective score
items were assessed individually as potential diagnostic
tests for predicting in-stent restenosis in patients who
underwent CAS.
All statistical analyses were performed with Stata 11
(StataCorp, College Station, Texas).
Results
A total of sixty patients (48 men and 12 women) treated
with CAS were analyzed in this study including 10 cases
(patients with ISR) and 50 controls without ISR. Cases
and controls showed no significant differences with re-




Age, years 69.8 ± 7.6
Female sex 4 (40%)
Right side 6 (60%)
Symptomatic carotid stenosis 4 (40%)
Stroke 2 (20%)
Hemispherical TIA 2 (20%)
Arterial Hypertension 10 (100%)
Hyperlipidemia 10 (100%)
Tobacco use 4 (40.0%)
Diabetes mellitus 2 (20%)
Coronary artery disease 3 (30%)
Peripheral occlusive arterial disease 3 (30%)
Atrial fibrillation 1 (12.5%)
CEA restenosis 3 (30%)
Contralateral ICA occlusion 3 (30%)
Contralateral ICA stenosis ≥70% 2 (20%)
Stenosis≥ 90% before CAS 7 (70%)
Median follow-up time (month, IQR) 15 (4.7 - 35.4)
PSV >120 cm/s after CAS 4 (40%)
Re-interventions 6 (60%)
*significant difference.degree of stenosis (Table 2). ISR cases were followed up
for longer (p = 0.024) and were more likely to show in-
creased PSV (p = 0.012) post intervention than controls.
Evaluation of plaque morphology
When investigating plaque morphology before CAS all
patients in the ISR group as well as in the control group
met the criteria of stenosis degree >40%.
Echogenicity was scored as described by Prati et al.
[13]. In the ISR group 50% (5 of 10 patients) met the cri-
teria for score 1, 30% (3 of 10 patients) for score 2 and
20% (2 of 10 patients) for score 3. The mean score in the
ISR group was 1,7. In comparison, in the control group
34% scored 1 (17 of 50 patients), 54% scored 2 (27 of 50
patients) and 12% scored 3 (6 of 50 patients) with a
mean echogenicity score of 1.78. No significant differ-
ence was detectable between the two groups (p = 0,46).
As the degree of hyperechogenicity correlates with the
calcification and might also be beneficial, in contrast to
a “soft plaque”, we also reversed the TPRS scoring sys-
tem in this point scoring 1 for hyperechogenicity and 3
for low echogenicity. This sub score showed a hypere-
chogenicity in 2 of 10 patients (20%) in the ISR group
and in 6 of 50 patients (12%) in the group of patientsData
No ISR p value
50

















40.2 (26.7 – 59.3) 0.024*
3 (6%) 0.012
0 (0%) <0.001
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ISR (50%) and in 17 of 50 patients without ISR (34%).
The mean of the reversed echogenicity score was 3,8
in the ISR group and 3,44 in the group without ISR
(p = 0,46).
Texture was described as homogenous (score 0) or het-
erogeneous (score 1). In the ISR group 40% (4/10 patients)
scored 0 and 60% (6/10 patients) scored 1, whereas 46%
(23/50 patients) scored 0 and 54% (27/50 patients) scored
1 in the control group. Again no significant difference be-
tween the two groups was detectable (p = 0,53).
The surface was described as either smooth (score 0) or
irregular (score 1). In the ISR group 10% (1/10 patients)
scored 0 and 90% (9/10 patients) scored 1, whereas 34%
(17/50 patients) scored 0 and 66% (33/50 patients) scored
1 in the control group. Again no significant difference be-
tween the two groups was detectable (p = 0,62).
In the next step, we performed a ROC analysis for
TPRS as well as for all individual parameters and calcu-
lated sensitivity and specificity, as well as negative pre-
dictive value and positive predictive value for each
parameter (Table 3). Neither the TPRS score nor one of
the individual parameters showed an acceptable validity
so that it could be used as a predictive diagnostic test
for ISR in patients undergoing CAS.
Discussion
CAS might be the therapy of choice for patients younger
than 70 years [5,9-11]. The on average young age of
CAS patients highlights the importance of a good long-
term clinical outcome and the need for potentially pre-
dictive factors concerning the development of an ISR.
Although different approaches, especially regarding la-
boratory parameters, have been made no reliable param-
eter is available to date which can sufficiently predict an
increased risk of ISR [14,21,26,27].
Duplex sonography (DUS) has been proven over years
to be able to assess carotid plaque morphology with
regards to plaque surface and the plaque structure. In
2004 Willfort-Ehringer and co-workers applied DUS to as-
sess the influence of pre- interventional plaque mor-
phology on Stent expansion in a 2 years follow up studyTable 3 Diagnostic validity and statistical data
TPRS Inverse TPRS
AUC (95%CI) 0.54 0.64
(0.36-0.72) (0.45-0.83)





*Positive and negative predictive value given the ISR prevalence of 0.06 in the over[28]. They evaluated the plaque morphology concerning
the echoluency of the preinterventional plaque and dis-
criminated between 7 different plaque types ranging from
soft to very hard with extensive shadowing. They found
that an increased calcification of the pre-interventional
plaque composition is associated with a decrease of stent
expansion [28] which is known as a risk factor for the
development of ISR [12,22].
Bearing these studies in mind we sought to study the
influence of pre-interventional plaque morphology on
ISR by an easy to use and reliable plaque scoring system.
Intima injury is supposed to be the initial trigger of
ISR. Petric et al. showed that the risk of intima injury
was lower in calcified plaques in comparison to soft pla-
ques strengthening the hypothesis of the “vulnerable”
soft plaque [19]. Therefore, it could be possible that a
soft plaque may be associated with a higher risk of the
development of an ISR.
We retrospectively analyzed the ultrasound data of pa-
tients who underwent CAS in our department between
2003 and 2012 and analyzed the plaque morphology re-
garding to the TPR score published by Prati et al. [13].
Interestingly we were not able to detect any influence of
either scoring parameters on the occurrence of ISR in the
course of the evaluation. But, as described by Willfort-
Ehringer and us earlier, we were also able to correlate the
echogenicity of the preinterventional plaque with the oc-
currence of incomplete stenosis dilatation, which is, as we
were able to show earlier and again an independent indi-
cator for ISR occurrence [12,28].
One main shortcoming of our study, besides the retro-
spective design, is the small sample size. We were only
able to analyze the data of 10 patients suffering from an
ISR and 50 controls, leaving this study underpowered
for the detection of small differences within the analyzed
factors. However, the results of this study provide evi-
dence that no plaque parameter within the TPRS is able
to predict ISR in CAS patients with acceptable validity.
Conclusion
In the present study we sought to evaluate a standard,
easy to use, broadly applicable and reliable system. ItEcho-genicity Texture Surface
0.46 0.53 0.62
(0.25-0.67) (0.36-0.70) (0.50-0.74)





all population of CAS-treated individuals of this study.
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the pre-interventional plaque formation is not sufficient
enough and it would be more advisable to investigate a
more sophisticated approach either by ultrasound based
plaque perfusion imaging, or CT based plaque analysis,
lacking the immediate broad applicability. In summary,
the pre-interventional assessment of plaque morphology
with conventional DUS by using the TPRS is not useful
in order to distinguish between patients who are likely
to suffer from ISR. Further studies will need to analyze
prospectively the usefulness of e.g. Plaque perfusion
techniques and DUS or CT techniques in order to re-
evaluate pre-interventional plaques as possible predictive
markers for the development of ISR.
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